CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

This study tests CAR-T cell therapy (immune cells engineered to attack cancer) combined with a drug called dasatinib for people with relapsed or refractory blood cancers including certain types of leukemia (ALL), lymphoma (NHL), or multiple myeloma (MM) that have not responded to standard treatments. **You may be eligible if...** - You have confirmed CD19-positive ALL, CD19-positive NHL, or BCMA-positive multiple myeloma - Your cancer has relapsed or not responded after standard treatment (e.g., multiple relapses, failure of induction therapy, relapse after stem cell transplant) - Your liver, kidney, and heart function meet required levels - Your overall health/functional status is adequate (ECOG 0–2) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your cancer does not express the target protein (CD19 or BCMA) - You have active lung infection or very low blood oxygen - Your organ function is inadequate - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.